Microbial Secondary Metabolites

Comprehensive Biotechnology, Second Edition

Volumn 3, Issue , 2011, Pages 285-297

  Marinelli, F ^a   Marcone, G L ^a  

^a UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

Antibacterials; Anticancers; Antifungals; Antivirals; Fermentation; Immunosuppressants; Microbial product screening; Secondary metabolites; Statins; Strain Improvement

Indexed keywords

EID: 85012819682     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-08-088504-9.00539-0     Document Type: Chapter

References (30)

1. Bu'Lock J. Intermediary metabolism and antibiotic synthesis. Advances in Applied Microbiology 1961, 3:293-342.
2. Demain A.L., Adrio J.L. Contributions of microorganisms to industrial biology. Molecular Biotechnology 2008, 38:41-55.
3. Fajardo A., Martinez J.L. Antibiotics as signals that trigger specific bacterial responses. Current Opinion in Microbiology 2008, 11:161-167.
4. Challis G.L., Hopwood D.A. Synergy and contingency as driving forces for the evolution of multiply secondary metabolite production by Streptomyces species. Proceedings of the National Academy of Sciences of the United States of America 2003, 25:14555-14561.
5. Vining L.C. Functions of secondary metabolites. Annual Review of Microbiology 1990, 44:395-427.
6. Davies J., Spiegelman G.B., Yim G. The world of subinhibitory antibiotic concentrations. Current Opinion in Microbiology 2006, 9:445-453.
7. Osbourn A. Secondary metabolic gene clusters: Evolutionary toolkits for chemical innovation. Trends in Genetics 2010, 26:449-457.
8. Berdy J. Bioactive microbial metabolites. Journal of Antibiotics (Tokyo) 2005, 58:1-26.
9. Banik J.J., Brady S.F. Recent application of metagenomic approaches toward the discovery of antimicrobials and other bioactive small molecules. Current Opinion in Microbiology 2010, 13:603-609.
10. Marinelli F. From microbial products to novel drugs that target a multitude of disease indications. Methods in Enzymology 2009, 458:29-58.
11. Wang J., Soisson S.M., Young K., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006, 441:358-361.
12. Jovetic S., Zhu Y., Marcone G.L., et al. β-Lactam and glycopeptide antibiotics: First and last line of defense?. Trends in Biotechnology 2010, 28(12):596-604.
13. Moy T.I., Ball A.R., Anklesaria Z., et al. Identification of novel antimicrobials using a live-animal infection model. Proceedings of the National Academy of Sciences of the United States of America 2006, 103:10414-10419.
14. Di Santo R. Natural products as antifungal agents against clinically relevant pathogens. Natural Product Reports 2010, 27:1084-1098.
15. Cragg G.M., Grothaus P.G., Newman D.J. Impact of natural products on developing new anticancer agents. Chemical Reviews 2009, 109:3012-3043.
16. Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. Journal of Natural Products 2007, 70:461-477.
17. Bibb M.J. Regulation of secondary metabolism in streptomycetes. Current Opinion in Microbiology 2005, 8:208-215.
18. Sanchez S., Demain A.L. Metabolic regulation of fermentation processes. Enzyme and Microbial Technology 2002, 31:895-906.
19. Kennedy J. Mutasynthesis, chemobiosynthesis, and back to semi-synthesis: Combining synthetic chemistry and biosynthetic engineering for diversifying natural products. Natural Product Research 2007, 25:25-34.
20. Olano C., Lombò F., Méndez C., Salas J.A. Improving production of bioactive secondary metabolites in actinomycetes by metabolic engineering. Metabolic Engineering 2008, 10:281-292.
21. Fischbach M.A., Walsh C.T. Antibiotics for emerging pathogens. Science 2009, 325:1089-1093.
22. Robbel L., Marahiel M.A. Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. The Journal of Biological Chemistry 2010, 285:27501-27508.
23. Vaara M. Polymyxins and their novel derivatives. Current Opinion in Microbiology 2010, 13:574-581.
24. Zazopoulos E., Huang K., Staffa A., et al. A genomics-guided approach for discovering and expressing cryptic metabolic pathways. Nature Biotechnology 2003, 21:187-190.
25. Strobel G. Harnessing endophytes for industrial microbiology. Current Opinion in Microbiology 2006, 9:240-244.
26. Reichenbach H., Hofle G. Discovery and development of the epothilones: A novel class of antineoplastic drugs. Drugs in R & D 2008, 9:1-10.
27. Mann J. Natural products as immunosuppressive agents. Natural Product Reports 2001, 18:417-430.
28. Borel J.F., Kis Z.L. The discovery and development of cyclosporine (Sandimmune). Transplantation Proceedings 1991, 23:1867-1874.
29. Sehgal S.N. Sirolimus: Its discovery, biological properties, and mechanism of action. Transplantation Proceedings 2003, 35:7S-14S.
30. Barrios-Gonzalez J., Miranda R.U. Biotechnological production and applications of statins. Applied Microbiology and Biotechnology 2010, 85:869-883.